These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 28477683)

  • 41. Soluble interleukin-6 receptor (sIL-6R) in cerebrospinal fluid of patients with inflammatory and non inflammatory neurological diseases.
    Michalopoulou M; Nikolaou C; Tavernarakis A; Alexandri NM; Rentzos M; Chatzipanagiotou S; Cambouri C; Vassilopoulos D
    Immunol Lett; 2004 Jul; 94(3):183-9. PubMed ID: 15275965
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tau protein and 14-3-3 are elevated in the cerebrospinal fluid of patients with multiple sclerosis and correlate with intrathecal synthesis of IgG.
    Bartosik-Psujek H; Archelos JJ
    J Neurol; 2004 Apr; 251(4):414-20. PubMed ID: 15083285
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Soluble interleukin-2 receptor and soluble CD8 molecules in cerebrospinal fluid and serum of patients with multiple sclerosis.
    Carrieri PB; Soscia E; Iacovitti B; Pellicano M; D'Antonio A; Provitera V; Perrella O
    Eur Cytokine Netw; 1992; 3(5):495-8. PubMed ID: 1477299
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein.
    Novakova L; Zetterberg H; Sundström P; Axelsson M; Khademi M; Gunnarsson M; Malmeström C; Svenningsson A; Olsson T; Piehl F; Blennow K; Lycke J
    Neurology; 2017 Nov; 89(22):2230-2237. PubMed ID: 29079686
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Decreased Cerebrospinal Fluid Antioxidative Capacity Is Related to Disease Severity and Progression in Early Multiple Sclerosis.
    Voortman MM; Damulina A; Pirpamer L; Pinter D; Pichler A; Enzinger C; Ropele S; Bachmaier G; Archelos JJ; Marsche G; Khalil M
    Biomolecules; 2021 Aug; 11(9):. PubMed ID: 34572477
    [No Abstract]   [Full Text] [Related]  

  • 46. Changes in Serum Ceruloplasmin Levels Based on Immunomodulatory Treatments and Melatonin Supplementation in Multiple Sclerosis Patients.
    Adamczyk-Sowa M; Sowa P; Mucha S; Zostawa J; Mazur B; Owczarek M; Pierzchała K
    Med Sci Monit; 2016 Jul; 22():2484-91. PubMed ID: 27420299
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis.
    Scalabrino G; Galimberti D; Mutti E; Scalabrini D; Veber D; De Riz M; Bamonti F; Capello E; Mancardi GL; Scarpini E
    Brain Res; 2010 May; 1333():64-71. PubMed ID: 20347721
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tetranectin in cerebrospinal fluid of patients with multiple sclerosis.
    Stoevring B; Jaliashvili I; Thougaard AV; Ensinger C; Høgdall CK; Rasmussen LS; Sellebjerg F; Christiansen M
    Scand J Clin Lab Invest; 2006; 66(7):577-83. PubMed ID: 17101549
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neuronal antigens recognized by cerebrospinal fluid IgM in multiple sclerosis.
    Beltrán E; Hernández A; Lafuente EM; Coret F; Simó-Castelló M; Boscá I; Pérez-Miralles FC; Burgal M; Casanova B
    J Neuroimmunol; 2012 Jun; 247(1-2):63-9. PubMed ID: 22498100
    [TBL] [Abstract][Full Text] [Related]  

  • 50. KFLC Index utility in multiple sclerosis diagnosis: Further confirmation.
    Pieri M; Storto M; Pignalosa S; Zenobi R; Buttari F; Bernardini S; Centonze D; Dessi M
    J Neuroimmunol; 2017 Aug; 309():31-33. PubMed ID: 28601282
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Epstein-Barr virus-specific intrathecal oligoclonal IgG production in relapsing-remitting multiple sclerosis is limited to a subset of patients and is composed of low-affinity antibodies.
    Castellazzi M; Contini C; Tamborino C; Fasolo F; Roversi G; Seraceni S; Rizzo R; Baldi E; Tola MR; Bellini T; Granieri E; Fainardi E
    J Neuroinflammation; 2014 Nov; 11():188. PubMed ID: 25391491
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of corticosteroid therapy on serum and CSF malondialdehyde and antioxidant proteins in multiple sclerosis.
    Keles MS; Taysi S; Sen N; Aksoy H; Akçay F
    Can J Neurol Sci; 2001 May; 28(2):141-3. PubMed ID: 11383939
    [TBL] [Abstract][Full Text] [Related]  

  • 53. BAFF is up-regulated in central nervous system of neuro-Behçet's disease.
    Hamzaoui K; Houman H; Hentati F; Hamzaoui A
    J Neuroimmunol; 2008 Aug; 200(1-2):111-4. PubMed ID: 18625522
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Elevated levels of a soluble form of the T cell activation antigen CD27 in cerebrospinal fluid of multiple sclerosis patients.
    Hintzen RQ; van Lier RA; Kuijpers KC; Baars PA; Schaasberg W; Lucas CJ; Polman CH
    J Neuroimmunol; 1991 Dec; 35(1-3):211-7. PubMed ID: 1659587
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Soluble interleukin-2 receptors in cerebrospinal fluid from individuals with various neurological disorders.
    Kittur SD; Kittur DS; Soncrant TT; Rapoport SI; Tourtellotte WW; Nagel JE; Adler WH
    Ann Neurol; 1990 Aug; 28(2):168-73. PubMed ID: 2221845
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intrathecal chitotriosidase and the outcome of multiple sclerosis.
    Sotgiu S; Barone R; Arru G; Fois ML; Pugliatti M; Sanna A; Rosati G; Musumeci S
    Mult Scler; 2006 Oct; 12(5):551-7. PubMed ID: 17086899
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Excitatory amino acids and multiple sclerosis: evidence from cerebrospinal fluid.
    Sarchielli P; Greco L; Floridi A; Floridi A; Gallai V
    Arch Neurol; 2003 Aug; 60(8):1082-8. PubMed ID: 12925363
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Microglial/macrophage markers CHI3L1, sCD14, and sCD163 in CSF and serum of pediatric inflammatory and non-inflammatory neurological disorders: A case-control study and reference ranges.
    Pranzatelli MR; Tate ED; McGee NR
    J Neurol Sci; 2017 Oct; 381():285-290. PubMed ID: 28991699
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Serum and cerebrospinal fluid soluble Fas levels in clinical subgroups of multiple sclerosis.
    Boylan MT; Crockard AD; McDonnell GV; McMillan SA; Hawkins SA
    Immunol Lett; 2001 Oct; 78(3):183-7. PubMed ID: 11578693
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Serum ferroxidase I and II in uremic patients under conservative treatment and maintenance hemodialysis.
    Frangos-Plemenos M; Agroyannis B; Koutsicos D; Tzanatos-Exarchou H; Logothetis E; Sarris E; Kaya S; Yatzidis H
    Int J Artif Organs; 1987 May; 10(3):195-8. PubMed ID: 3610372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.